These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
Amazon may be pushing for retail sales via EHRs, but it's just one move in its bigger strategic play around data and patients' electronic health…
Sanofi's new partnership with Mount Sinai Health System and advanced analytics firm Sema4 will create a digital asthma laboratory.
With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.…
J&J’s clot-busting Xarelto may not have hit the primary goal in its latest trial, but the company still believes it can win a new approval down the line.
Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated CLL. But the partners are looking to own it.
Last month, Seattle Genetics scored a fast FDA nod for Adcetris in patients with newly diagnosed peripheral T-cell lymphoma, and new data show why.
Seattle Genetics CEO Clay Siegall was impressed by the FDA's first speedy real-time review nods, but his company would soon win an even faster OK.
As the federal comment deadline looms, detractors are challenging the value of adding drug prices to pharma TV ads.